"The advent of predictive biomarker testing on tissue samples for targeted therapy has forever altered the role of the pathologist in the management of patients with lung cancer."

http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2013-0319-CR

Arch Pathol Lab Med. 2013 Sep;137(9):1191-8. doi: 10.5858/arpa.2013-0319-CR.

Lung cancer biomarkers: present status and future developments.

Cagle PT, Allen TC, Olsen RJ.

The advent of predictive biomarker testing on tissue samples for targeted therapy has forever altered the role of

the pathologist in the management of patients with lung cancer. The role of the pathologist in biomarker testing,

including very direct participation with IHC, has potential to grow. Patients with lung cancer and their families are now

more aware of who pathologists are and the critical role that they have in their health care. New tests, new test

technologies, and overall advances in precision medicine will likely improve the cost to benefit ratio for biomarker

testing which, along with the powerful desire from patients and physicians to improve survival and quality of life,

suggest that predictive biomarker testing will expand as a routine component of cancer care.